Symbiotic microbiome Staphylococcus epidermidis restricts IL-33
production in allergic nasal epithelium by limiting cellular necroptosis
Abstract
Remarkable progress has recently been achieved to identify the
biological function and potential value of interleukin (IL)-33 as a
novel therapeutic target of allergic rhinitis (AR) at the nasal
epithelium level. 1-4 The nasal mucosa is constantly
exposed to inhaled allergens, and insights into the microbiota of human
nasal mucosa can provide fundamental information on factors contributing
to related allergic inflammation. 5 However, a
mechanistic consideration of immunomodulatory properties of the nasal
microbiome to inhaled allergens has not been comprehensively performed
in AR. The purpose of this study was to show the distinctive role of the
nasal microbiome S. epidermidis, a major symbiont in healthy
nasal mucus, and the potential impact on reduction of T helper (Th)2
inflammation through decreased cellular necroptosis and subsequent IL-33
release in nasal epithelium.